Cagrilintide
Neutral technical record and index of the peer-reviewed literature referencing Cagrilintide. For research use only — no human or veterinary use, benefit, or dosing information is provided.
Identity
| PubChem CID | 171397054 |
|---|---|
| CAS number | 1415456-99-3 |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409 g/mol |
| InChIKey | LDERDVMBIYGIOI-IZVMHKDJSA-N |
What it is
Cagrilintide is a long-acting synthetic amylin analogue peptide. It belongs to the class of amylin receptor agonists. It is supplied as lyophilized material for research use only.
Mechanism (technical)
Cagrilintide has been studied for its action on amylin and calcitonin receptors, pathways associated with the regulation of food intake and glucose homeostasis. In clinical pharmacology studies it has been investigated alone and in combination with the GLP-1 receptor agonist semaglutide. Pharmacodynamic endpoints have characterized these receptor-mediated effects.
Peer-reviewed literature
5 studies indexed · 5 human. Listed neutrally; outcome studies are indexed, not endorsed.
- Cagrilintide-Semaglutide in Overweight/Obesity and T2D (REDEFINE 2)Davies MJ, et al. · 2025 · N Engl J Med · RCT · human
- Coadministered Cagrilintide and Semaglutide in Overweight or Obesity (REDEFINE 1)Garvey WT, et al. · 2025 · N Engl J Med · RCT · human
- Cagrilintide 2.4 mg with semaglutide 2.4 mg in T2D: phase 2 trialFrias JP, et al. · 2023 · Lancet · RCT · human
- Cagrilintide + semaglutide 2.4 mg: phase 1b safety/PK/PD trialEnebo LB, et al. · 2021 · Lancet · clinical trial · human
- Once-weekly cagrilintide for weight management: phase 2 dose-finding trialLau DCW, et al. · 2021 · Lancet · RCT · human
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Sold to qualified researchers for laboratory research purposes only.